Hydroxymethylglutaryl-CoA Reductase Inhibitors
"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.
| Descriptor ID |
D019161
|
| MeSH Number(s) |
D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
|
| Concept/Terms |
Hydroxymethylglutaryl-CoA Reductase Inhibitors- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Hydroxymethylglutaryl CoA Reductase Inhibitors
- Inhibitors, Hydroxymethylglutaryl-CoA Reductase
- Reductase Inhibitors, Hydroxymethylglutaryl-CoA
- Inhibitors, HMG-CoA Reductase
- Inhibitors, HMG CoA Reductase
- Reductase Inhibitors, HMG-CoA
- HMG-CoA Reductase Inhibitors
- HMG CoA Reductase Inhibitors
- Statins, HMG-CoA
- HMG-CoA Statins
- Statins, HMG CoA
- Inhibitors, Hydroxymethylglutaryl-CoA
- Hydroxymethylglutaryl-CoA Inhibitors
- Inhibitors, Hydroxymethylglutaryl CoA
- Statins
- Inhibitors, Hydroxymethylglutaryl-Coenzyme A
- Hydroxymethylglutaryl-Coenzyme A Inhibitors
- Inhibitors, Hydroxymethylglutaryl Coenzyme A
|
Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".
This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 2 | 0 | 2 |
| 1997 | 3 | 0 | 3 |
| 1998 | 2 | 1 | 3 |
| 1999 | 2 | 0 | 2 |
| 2000 | 2 | 3 | 5 |
| 2001 | 5 | 1 | 6 |
| 2002 | 6 | 3 | 9 |
| 2003 | 17 | 4 | 21 |
| 2004 | 16 | 4 | 20 |
| 2005 | 16 | 3 | 19 |
| 2006 | 12 | 3 | 15 |
| 2007 | 15 | 4 | 19 |
| 2008 | 21 | 11 | 32 |
| 2009 | 14 | 4 | 18 |
| 2010 | 9 | 3 | 12 |
| 2011 | 12 | 2 | 14 |
| 2012 | 7 | 3 | 10 |
| 2013 | 9 | 2 | 11 |
| 2014 | 11 | 9 | 20 |
| 2015 | 7 | 3 | 10 |
| 2016 | 7 | 4 | 11 |
| 2017 | 12 | 4 | 16 |
| 2018 | 4 | 3 | 7 |
| 2019 | 7 | 4 | 11 |
| 2020 | 5 | 1 | 6 |
| 2021 | 5 | 0 | 5 |
| 2022 | 9 | 0 | 9 |
| 2023 | 9 | 1 | 10 |
| 2024 | 1 | 2 | 3 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.
-
Safety and efficacy of atorvastatin for rebleeding in cerebral cavernous malformations (AT CASH EPOC): a phase 1/2a, randomised placebo-controlled trial. Lancet Neurol. 2025 Apr; 24(4):295-304.
-
Management of Patients With Chronic Coronary Disease. JAMA. 2024 08 20; 332(7):585-586.
-
Obicetrapib on top of maximally tolerated lipid-modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN. Am Heart J. 2024 08; 274:32-45.
-
Greater use of antihypertensive medications explains lower blood pressures and better control in statin-treated than statin-eligible untreated adults. J Hypertens. 2024 Apr 01; 42(4):711-717.
-
Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments. Curr Atheroscler Rep. 2024 02; 26(2):35-44.
-
Structure of human drug transporters OATP1B1 and OATP1B3. Nat Commun. 2023 09 18; 14(1):5774.
-
Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2023 10; 43(10):e404-e442.
-
Association of Statin Use With Risk of Stroke Recurrence After Intracerebral Hemorrhage. Neurology. 2023 10 31; 101(18):e1793-e1806.
-
Repurposing medications for treatment of age-related macular degeneration: Insights from novel approaches to data mining. Exp Biol Med (Maywood). 2023 05; 248(9):798-810.
-
Obicetrapib plus ezetimibe as an adjunct to high-intensity statin therapy: A randomized phase 2 trial. J Clin Lipidol. 2023 Jul-Aug; 17(4):491-503.